Stockscreener 앱 받기
7.86
4.94%
0.37
시간 외 거래:
8.00
0.14
+1.78%
Astria Therapeutics Inc 주식(ATXS)의 최신 뉴스
Astria Therapeutics (NASDAQ:ATXS) Earns Outperform Rating from Analysts at JMP Securities - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Upgraded by Citizens Jmp to Strong-Buy Rating - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Up 25.7% in January - MarketBeat
Astria wins new Outperform rating at JMP on drug technology - MSN
Astria stock wins new Outperform at JMP (ATXS:NASDAQ) - Seeking Alpha
JMP Securities Initiates Astria Therapeutics at Outperform -January 31, 2025 at 08:17 am EST - Marketscreener.com
JMP Securities starts Astria Therapeutics stock with $26 target By Investing.com - Investing.com Canada
JMP Securities starts Astria Therapeutics stock at Market Outperform By Investing.com - Investing.com UK
JPMorgan Chase & Co. Increases Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
What To Expect From Astria Therapeutics In Q4 - RTTNews
Astria Therapeutics (NASDAQ:ATXS) Earns “Buy” Rating from HC Wainwright - Defense World
HC Wainwright Reaffirms "Buy" Rating for Astria Therapeutics (NASDAQ:ATXS) - MarketBeat
H.C. Wainwright sets $16 target on Astria Therapeutics stock - MSN
Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis - Business Wire
Astria Therapeutics Launches Phase 1a Trial of Novel Atopic Dermatitis Treatment STAR-0310 - StockTitan
Where are the Opportunities in (ATXS) - Stock Traders Daily
Astria Therapeutics, Inc. (NASDAQ:ATXS) Sees Large Increase in Short Interest - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.60 Consensus Price Target from Brokerages - Defense World
HC Wainwright Reaffirms “Buy” Rating for Astria Therapeutics (NASDAQ:ATXS) - Defense World
Barclays PLC Has $1.02 Million Stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics (NASDAQ:ATXS) Receives Buy Rating from HC Wainwright - MarketBeat
Astria Therapeutics plans phase 3 trial for HAE drug - Investing.com
Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE - Business Wire
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Rating of "Buy" from Analysts - MarketBeat
Jane Street Group LLC Has $404,000 Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Jane Street Group LLC Cuts Stock Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Astria Therapeutics Awards Stock Options to New Employees Under Inducement Plan - StockTitan
Geode Capital Management LLC Trims Stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Geode Capital Management LLC Has $10.50 Million Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Barclays PLC Boosts Stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics, Inc. (NASDAQ:ATXS) Sees Large Decrease in Short Interest - MarketBeat
(ATXS) Investment Analysis - Stock Traders Daily
Astria Therapeutics (NASDAQ:ATXS) Stock Price Down 3.4%Here's What Happened - MarketBeat
State Street Corp Reduces Stock Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
State Street Corp Sells 495,436 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) PT at $25.60 - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes $613,000 Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $613,000 in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Astria Therapeutics expands stock incentive plan - Investing.com
Astria Therapeutics Expands Stock Incentive Plan - TipRanks
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.60 Consensus PT from Brokerages - MarketBeat
Is Astria Therapeutics (ATXS) Stock Outpacing Its Medical Peers This Year? - MSN
Short Interest in Astria Therapeutics, Inc. (NASDAQ:ATXS) Grows By 8.6% - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Charles Schwab Investment Management Inc. Has $3.46 Million Stock Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
ATXSAstria Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Astria’s OX40 antagonist gains US IND clearance for atopic dermatitis - BioWorld Online
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE - Business Wire
FDA clears Astria Therapeutics' new AD drug for trial By Investing.com - Investing.com Canada
Astria's Navenibart Shows Remarkable 95% HAE Attack Reduction in Phase 1b/2 Trial Results - StockTitan
Astria Therapeutics, Inc. Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis - Marketscreener.com
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis - Business Wire
Astria Therapeutics' Novel Atopic Dermatitis Drug STAR-0310 Gets FDA Green Light for Clinical Trials - StockTitan
(ATXS) Long Term Investment Analysis - Stock Traders Daily
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Bought by Fmr LLC - Defense World
Fmr LLC Buys 1,767,714 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
3.95%
2.39%
자본화:
|
볼륨(24시간):